Biomarkers
Unleashing precision: A review of targeted approaches in pleural mesothelioma
Critical Reviews in Oncology and Hematology 2024 August 17 [Link] Mario Occhipinti, Marta Brambilla, Raimondo Di Liello, Paolo Ambrosini, Lorenzo Lobianco, Rita Leporati, Maria Salvarezza, Fabiana Vitiello, Silvia Marchesi, Sara Manglaviti, Teresa Beninato, Laura Mazzeo, Claudia Proto, Arsela Prelaj, Roberto Ferrara, Carminia Maria Della Corte, Giuseppe Lo Russo, Filippo de Braud, Monica Ganzinelli, Giuseppe Viscardi…
Read MoreVolatile Organic Compound Analysis of Malignant Pleural Mesothelioma Chorioallantoic Membrane Xenografts
Journal of Breath Research 2024 August 20 [Link] Liam David Little, Sarah E Barnett, Theo Issitt, Sam Bonsall, Vikki Amanda Carolan, K Elizabeth Allen, Laura Margaret Cole, Neil A Cross, Judy M Coulson, Sarah Louise Haywood-Small Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with asbestos exposure. MPM is often diagnosed late, at…
Read MorePleural fluid biomarkers: a narrative review
Journal of Thoracic Disease 2024 July 30 [Link] Christopher Chan, Ken Ka Pang Chan Abstract Background and objective: Pleural fluid is a source from which various biomarkers can be obtained and measured to facilitate the management and prognostication of various conditions. This narrative review aims to summarise a few selected applications of pleural fluid biomarker…
Read MoreCombined detection of SHOX2 and PTGER4 methylation with serum marker CYFRA21-1 for improved diagnosis of malignant pleural mesothelioma
Journal of Clinical Pathology 2024 July 26 [Link] Nana Zhang, Yongmeng Li, Zuyu Sun, Yujie Dong, Lijuan Zhou, Chen Zhang, Zichen Liu, Qiuyi Zhang, Kun Li, Fudong Xu, Li Zhang, Bin She, Xiaosha Ren, Nanying Che Abstract Aims: To investigate the performance of a combined biomarker approach using the methylation status of the short stature…
Read MoreCharacterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma
Scientific Reports 2024 July 10 [Link] Riki Okita, Tomoya Senoo, Yuka Mimura-Kimura, Yusuke Mimura, Tomoyuki Murakami, Eiji Ikeda, Masanori Okada, Hidetoshi Inokawa, Keisuke Aoe Abstract The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of…
Read MoreGenomic and T cell repertoire biomarkers associated with malignant mesothelioma survival
Thoracic Cancer 2024 May 27 [Link] Muwen Nie, Zhao Sun, Ningning Li, Liangrui Zhou, Shuchun Wang, Mingming Yuan, Rongrong Chen, Lin Zhao, Ji Li, Chunmei Bai Abstract Background: Malignant mesothelioma (MM) is an exceedingly rare tumor with poor prognosis due to the limited availability of effective treatment. Immunotherapy has emerged as a novel treatment approach…
Read MoreDifferential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Translational Lung Cancer Research 2024 April 29 [Link] Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorecki Abstract Background: The identification of prognostic biomarkers is crucial for guiding treatment strategies in mesothelioma patients. The Duchenne muscular dystrophy (DMD) gene and its specific transcripts have been associated with patient survival in various tumours.…
Read MoreDifferential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Translational Lung Cancer Research 2024 April 29 [Link] Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorecki Abstract Background: The identification of prognostic biomarkers is crucial for guiding treatment strategies in mesothelioma patients. The Duchenne muscular dystrophy (DMD) gene and its specific transcripts have been associated with patient survival in various tumours.…
Read MoreBAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma
JTO Clinical and Research Reports 2024 March 29 [Link] Duo Xu, Yanyun Gao, Haitang Yang, Marc Spils, Thomas M Marti, Tereza Losmanová, Min Su, Wenxiang Wang, Qinghua Zhou, Patrick Dorn, Yongqian Shu, Ren-Wang Peng Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare and universally lethal malignancy with limited treatment options. Immunotherapy with immune checkpoint…
Read MorePleural mesothelioma from fluoro-edenite exposure: PACAP and PAC1 receptor. A preliminary report
European Journal of Histochemistry 2024 May 2 [Link] Claudia Lombardo, Grazia Maugeri, Agata Grazia D’Amico, Giuseppe Broggi, Rosario Caltabiano, Veronica Filetti, Serena Matera, Velia D’Agata, Carla Loreto Abstract Pleural mesothelioma is a devastating malignancy primarily associated with asbestos exposure. However, emerging evidence suggests that exposure to fluoro-edenite fibers, a naturally occurring mineral fiber, can also…
Read More